Video

Dr. Rana McKay on practice-changing trials in advanced renal cell carcinoma

Rana McKay, MD, describes the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials, which she says, “have largely changed the way we treat kidney cancer in the modern era for patients with advanced/metastatic disease.” McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.